Johnson & Johnson (JNJ)

114.60
NYSE : Health Care
Prev Close 114.60
Day Low/High 0.00 / 0.00
52 Wk Low/High 94.28 / 126.07
Avg Volume 7.25M
Exchange NYSE
Shares Outstanding 2.72B
Market Cap 311.77B
EPS 5.60
P/E Ratio 20.11
Div & Yield 3.20 (2.80%)

Latest News

JNJ, Actelion Reportedly Move Closer to a Deal

JNJ, Actelion Reportedly Move Closer to a Deal

A final deal could come as soon as this month, Bloomberg reported.

Trump Tax Policies Could Make J&J a Bigger Threat in 2017

Trump Tax Policies Could Make J&J a Bigger Threat in 2017

While there remains many unknowns about the specifics of possible legislation, CEO Alex Gorsky suggested that tax reform and repatriation could be a major game changer for J&J.

Johnson & Johnson Could Benefit From Tax Reform

Johnson & Johnson Could Benefit From Tax Reform

Johnson & Johnson could repatriate offshore profits in 2017 if a potential tax holiday is passed.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Shares of J&J and Procter & Gamble Could Be Ready to Break Out

Shares of J&J and Procter & Gamble Could Be Ready to Break Out

After a period of consolidation, several personal care products companies look like they are about to rally.

Johnson & Johnson CEO Gorsky Discusses What Drove the Stock in 2016

Johnson & Johnson CEO Gorsky Discusses What Drove the Stock in 2016

Johnson & Johnson CEO Alex Gorsky discusses the 16% rise in the company's stock over the last year.

The Charts Show These Two Blue Chips Are Poised for a Big Breakout

The Charts Show These Two Blue Chips Are Poised for a Big Breakout

These four personal-products stocks are poised for profits.

Technology Rules as Only S&P Sector Hitting a New High

Technology Rules as Only S&P Sector Hitting a New High

Of the 11 S&P 500 sectors, technology leads followed by gain from health care and consumer discretionary stocks. Here's how you trade these sectors using exchange-traded funds.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Too Few Stocks Doing Too Much: Jim Cramer's Best Blog

Too Few Stocks Doing Too Much: Jim Cramer's Best Blog

Jim Cramer ponders how too few stocks are doing too much in the Dow's race to 20,000 and how there isn't enough GANG to go with all the FANG.

Cramer: Too Few Stocks Are Doing Too Much in Dow's Run to 20,000

Cramer: Too Few Stocks Are Doing Too Much in Dow's Run to 20,000

Disney and Goldman are doing a lot of the heavy lifting.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Pfizer Unveils Positive Results from Study of Potential Humira Biosimilar

Pfizer Unveils Positive Results from Study of Potential Humira Biosimilar

Thursday's announcement marks Pfizer's third proposed biosimilar pipeline molecule to announce positive top-line results within the past four months.

Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs

Drug Giant Eli Lilly Wants to Save Money So it Brought in These New Bigwigs

One of the announcements include the hiring of former Novartis executive Christi Shaw to lead the biomedicines business starting April 3.

What Pharma and Health Care Investors Should Watch for at JPM

What Pharma and Health Care Investors Should Watch for at JPM

The largest investor conference for the health care industry kicks off on Monday in San Francisco.

3 Health Care Giants Set to Ride Out Washington's Sound and Fury

3 Health Care Giants Set to Ride Out Washington's Sound and Fury

An attempt to repeal the Affordable Care Act and the brewing policy war between President-elect Donald Trump and the Democrats won't slow these three health sector juggernauts.

Damage Award Against Johnson & Johnson Cut in Half by Judge

Damage Award Against Johnson & Johnson Cut in Half by Judge

A big damage award against J&J has been reduced by a judge, but the company is still facing thousands of additional claims.

Huge Johnson & Johnson Damage Award Slashed by Half

Huge Johnson & Johnson Damage Award Slashed by Half

The company still plans to appeal the judgment for faulty hip replacements.

See How Johnson & Johnson Ranks Among Analysts' Top Dow 30 Picks

See How Johnson & Johnson Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson is the #16 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, JNJ claims the #285 spot.

Watch Beaten-Down Drug Companies, Hospitals in 2017

Watch Beaten-Down Drug Companies, Hospitals in 2017

There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.

Dividend Stock Picks Could Look Even Better in Coming Weeks

Dividend Stock Picks Could Look Even Better in Coming Weeks

Technical analysis shows investors interested in Boeing, Abbott Labs, Johnson & Johnson and Cardinal Health may increase returns by holding off on purchases.

Top 5 Dividend Stocks to Buy Now for 2017

Top 5 Dividend Stocks to Buy Now for 2017

Here is a look at some stocks that are poised for excellent dividend returns in 2017.

Top 10 Dividend Stocks You Need to Buy Now to Prepare for 2017

Top 10 Dividend Stocks You Need to Buy Now to Prepare for 2017

Here's a look at the 10 best dividend stocks to invest in for potential outperformance in 2017.

Jim Cramer on Why Johnson & Johnson Returned to Actelion Talks

Jim Cramer on Why Johnson & Johnson Returned to Actelion Talks

Jim Cramer wonders whether someone at Johnson & Johnson is now willing to pay more for Actelion, or if there was more give from the other side.